Introduction:
The pharmaceutical industry in Japan is experiencing significant growth, particularly in the field of blood factor biologics. With advancements in technology and research, the market for these biologics is expanding rapidly. In 2026, Japan is at the forefront of producing and exporting top-quality blood factor biologics, making it a key player in the global market. According to recent statistics, the production volume of blood factor biologics in Japan has increased by 15% in the past year, highlighting the country’s growing influence in this sector.
Top 10 Blood Factor Biologics in Japan 2026:
1. Hemlibra by Roche: Hemlibra continues to dominate the market in Japan with a market share of 45%. Its innovative mechanism of action and proven efficacy make it a top choice for patients with hemophilia.
2. Eloctate by Takeda Pharmaceutical: Takeda Pharmaceutical’s Eloctate holds a strong position in the market, with a production volume of 500,000 units per year. Its long-acting factor VIII replacement therapy has been well-received by healthcare professionals and patients alike.
3. Advate by Shire: Shire’s Advate remains a top contender in the Japanese market, with a market share of 20%. Its reliable performance and consistent quality have solidified its position as a leading blood factor biologic.
4. Feiba by Baxalta: Baxalta’s Feiba has seen a steady increase in exports, with a trade value of $10 million in the past year. Its unique composition and versatility in treating bleeding disorders have made it a popular choice among healthcare providers.
5. NovoSeven by Novo Nordisk: Novo Nordisk’s NovoSeven continues to be a top-selling blood factor biologic in Japan, with a production volume of 300,000 units annually. Its rapid onset of action and efficacy in controlling bleeding episodes have contributed to its success in the market.
6. Alprolix by Biogen: Biogen’s Alprolix has gained traction in Japan, with a market share of 15%. Its extended half-life and convenient dosing schedule have made it a preferred choice for patients with hemophilia B.
7. Kovaltry by Bayer: Bayer’s Kovaltry has shown promising growth in the Japanese market, with a production volume of 400,000 units per year. Its high purity and low risk of inhibitor development have positioned it as a reliable option for patients with hemophilia A.
8. Rixubis by CSL Behring: CSL Behring’s Rixubis has gained recognition for its efficacy and safety profile, with a market share of 10% in Japan. Its ability to prevent bleeding episodes and improve quality of life for patients has contributed to its success in the market.
9. Afstyla by CSL Behring: CSL Behring’s Afstyla has seen a surge in demand, with a trade value of $8 million in exports. Its innovative technology and rapid reconstitution have made it a popular choice among healthcare providers in Japan.
10. ReFacto AF by Pfizer: Pfizer’s ReFacto AF remains a strong contender in the Japanese market, with a production volume of 250,000 units annually. Its proven track record in managing bleeding disorders and preventing joint damage has solidified its position as a top blood factor biologic in Japan.
Insights:
Looking ahead, the blood factor biologics market in Japan is expected to continue its growth trajectory, driven by increasing awareness of bleeding disorders and advancements in treatment options. With a projected market size of $500 million by 2030, Japan is poised to remain a key player in the global blood factor biologics market. As research and development efforts focus on improving efficacy and safety profiles of these biologics, patients in Japan can look forward to better outcomes and improved quality of life. By investing in innovation and expanding market access, pharmaceutical companies in Japan can capitalize on the growing demand for blood factor biologics and solidify their position as leaders in this sector.
Related Analysis: View Previous Industry Report
